



Patent Case No. CN01367K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#2  
3/10/02  
RECEIVED  
MAR 14 2002  
TECH CENTER 1600/2900

-----X  
In re Application of: **Stamford, et al.** :  
: Examiner: To Be Determined  
For: **HETEROARYL UREA NEUROPEPTIDE** :  
**Y Y5 RECEPTOR ANTAGONISTS** : Group Art Unit: To Be Determined  
Serial No.: 10/026,651 :  
Filed: December 18, 2001 :  
-----X  
Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

This statement is made in compliance with 37 C.F.R. 1.56, 1.97 and 1.98. The Examiner's attention is directed to the documents listed on the accompanying form PTO-1449.

These documents may be relevant to examination of the application. Inclusion of a document is not an admission that the document is prior art with respect to the invention of the application and is not to be construed as an admission that anything in the document renders any claim of the application unpatentable.


This statement is submitted before an action on the merits has been received, so no certification or fee is believed to be necessary.

A copy of each document is enclosed for the convenience of the Examiner.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231, on

March 1, 2002  
Date


ELLIOTT KORSEN  
Typed or Printed Name

  
Signature

March 1, 2002  
Date of Signature

Consideration of each document, and the return of an initialed copy of the duplicate copy of the enclosed form PTO-1449 to indicate such consideration, are respectfully requested.

Respectfully submitted,



Elliott Korsen  
Attorney for Applicant  
Registration No. 32,705  
Tel: 908-298-5684

March 1, 2002

Date

Schering-Plough Corporation  
Patent Department, K-6-1-1990  
2000 Galloping Hill Road  
Kenilworth, New Jersey 07033-0530